NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RGLS

Regulus Therapeutics Inc

Jun 24 • 04:00PM ET

8.16

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: IONS ARWR SRPT MRNA RNA ALNY SGMO PRQR WVE BBIO

| Held by: VTI VXF VTWO VTWV VTWG VTHR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.73	Insider Own	17.19%	Shs Outstand	66.28M	Perf Week	-0.73%
Market Cap	564.92M	Forward P/E	-	EPS next Y	-	Insider Trans	-1.36%	Shs Float	57.33M	Perf Month	3.16%
Enterprise Value	501.49M	PEG	-	EPS next Q	-	Inst Own	68.25%	Short Float	3.07%	Perf Quarter	466.67%
Income	-47.52M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.66	Perf Half Y	440.40%
Sales	0.00M	P/B	7.84	EPS next Y	-	ROA	-50.30%	Short Interest	1.76M	Perf YTD	416.46%
Book/sh	1.04	P/C	8.63	EPS next 5Y	-	ROE	-53.82%	52W High	8.35 -2.22%	Perf Year	223.81%
Cash/sh	0.95	P/FCF	-	EPS past 3/5Y	36.71% 40.21%	ROIC	-67.48%	52W Low	0.83 883.01%	Perf 3Y	236.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.32% 1.55%	Perf 5Y	-7.56%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	50.19%	Oper. Margin	-	ATR (14)	0.17	Perf 10Y	-99.36%
Dividend Ex-Date	-	Quick Ratio	15.52	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	66.62	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	15.52	EPS Q/Q	50.58%	SMA20	0.97%	Beta	0.36	Target Price	7.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	22.77%	Rel Volume	0.00	Prev Close	8.16
Employees	34	LT Debt/Eq	0.02	Earnings	May 08 AMC	SMA200	195.51%	Avg Volume	2.66M	Price	8.16
IPO	Oct 04, 2012	Option/Short	Yes / No	EPS/Sales Surpr.	38.78% -	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$3 → $6
Aug-02-24	Initiated	Oppenheimer	Outperform	$7
Mar-18-24	Initiated	Leerink Partners	Outperform	$6
Mar-28-18	Initiated	B. Riley FBR, Inc.	Neutral	$1
Jan-05-18	Initiated	Leerink Partners	Outperform	$2
Jun-13-17	Reiterated	Chardan Capital Markets	Buy	$5 → $2.50
Mar-06-17	Reiterated	Wedbush	Outperform	$8 → $6
Jan-30-17	Downgrade	Wells Fargo	Outperform → Market Perform
Jan-30-17	Downgrade	Needham	Buy → Hold
Dec-07-16	Reiterated	Chardan Capital Markets	Buy	$12 → $5
Nov-02-16	Reiterated	Needham	Buy	$10 → $9
Jul-25-16	Reiterated	Chardan Capital Markets	Buy	$14.50 → $12
Jun-28-16	Reiterated	Needham	Buy	$25 → $10
Jun-28-16	Reiterated	FBR Capital	Outperform	$30 → $9
Jun-28-16	Reiterated	Chardan Capital Markets	Buy	$20 → $13.50
Jun-07-16	Reiterated	Chardan Capital Markets	Buy	$15 → $20
Apr-13-16	Initiated	Chardan Capital Markets	Buy	$15
Dec-04-15	Initiated	Wells Fargo	Outperform
Jun-09-15	Initiated	Guggenheim	Buy
Apr-21-15	Resumed	FBR Capital	Outperform	$30

Show Previous Ratings

Jun-26-25 05:25AM	Novartis concludes Regulus Therapeutics acquisition (Pharmaceutical Technology)
Jun-25-25 09:13AM	Novartis completes acquisition of Regulus Therapeutics (GlobeNewswire)
01:00AM	Novartis announces expiration of Regulus Therapeutics tender offer (GlobeNewswire)
May-08-25 04:49PM	Regulus: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates (PR Newswire)
09:39AM	Loading…
May-02-25 09:39AM	Novartis to buy Regulus Therapeutics for as much as $1.7 billion (LA Times)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
07:26AM	Novartis to strengthen renal disease portfolio with Regulus (Pharmaceutical Technology)
Apr-30-25 04:30PM	Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements (Seeking Alpha) +136.80%
08:15AM	Novartis to acquire Regulus in deal for kidney disease drug (BioPharma Dive)
07:50AM	Novartis to Acquire Regulus in $1.7 Billion Deal (The Wall Street Journal)
07:24AM	Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal (Reuters)
07:00AM	Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG (PR Newswire)
Apr-24-25 09:55AM	Should You Buy Regulus (RGLS) After Golden Cross? (Zacks) +9.80%
Apr-18-25 03:25PM	Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts? (Insider Monkey)
08:00AM	Loading…
Apr-02-25 08:00AM	Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit (PR Newswire) +12.00%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha) +15.33%
Mar-27-25 07:00AM	Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +16.28%
Mar-19-25 12:00PM	What Makes Regulus (RGLS) a New Buy Stock (Zacks)
Mar-18-25 04:44AM	Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now (Insider Monkey)
Mar-13-25 04:18PM	Regulus: Q4 Earnings Snapshot (Associated Press Finance) -6.76% +7.25%
04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates (PR Newswire)
Mar-04-25 08:00AM	Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference (PR Newswire) +7.14%
Feb-21-25 03:42AM	Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently (Insider Monkey)
Feb-04-25 08:00AM	Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (PR Newswire) +8.94%
Jan-29-25 12:48PM	Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data (GuruFocus.com) -17.09%
07:00AM	Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) (PR Newswire)
Nov-26-24 08:00AM	Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences (PR Newswire)
Nov-07-24 05:13PM	Regulus: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates (PR Newswire)
06:01AM	Loading…
Oct-29-24 06:01AM	These 2 Strong Buy Penny Stocks Could Rally Over 500%, Say Analysts (TipRanks) +7.33%
Oct-08-24 08:00AM	Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -9.36%
Aug-28-24 08:00AM	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences (PR Newswire) -7.78%
Aug-08-24 05:19PM	Regulus: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates (PR Newswire)
Aug-06-24 08:00AM	Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference (PR Newswire)
Jul-09-24 08:00AM	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences (PR Newswire)
Jun-24-24 07:00AM	Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -18.33%
Jun-04-24 08:00AM	Regulus Therapeutics Announces Expected Addition to the Russell 3000 and Russell 2000 Indexes (PR Newswire)
May-16-24 08:00AM	Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer (PR Newswire)
May-09-24 10:57PM	RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
05:16PM	Regulus: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates (PR Newswire)
May-07-24 06:00AM	The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028 (InvestorPlace) -8.23%
May-06-24 08:00AM	Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -8.30%
Apr-30-24 08:00AM	Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series (PR Newswire) -8.73%
Mar-23-24 05:33AM	Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements (GuruFocus.com)
Mar-21-24 10:53PM	RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +11.20%
04:22PM	Regulus: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates (PR Newswire)
Mar-13-24 12:09PM	Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study (Zacks)
Mar-12-24 06:32AM	Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity (PR Newswire) +71.01%
06:30AM	Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Jan-02-24 04:05PM	Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Nov-22-23 08:00AM	Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire) -5.11%
Nov-09-23 04:32PM	Regulus: Q3 Earnings Snapshot (Associated Press Finance) -5.21%
04:05PM	Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates (PR Newswire)
Nov-02-23 08:00AM	Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +9.76%
Oct-19-23 08:00AM	Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Sep-20-23 07:00AM	Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -20.61%
Sep-13-23 08:00AM	Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +13.70%
Sep-05-23 08:00AM	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences (PR Newswire) +10.60%
Aug-24-23 07:33PM	Regulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap? (GuruFocus.com) +17.33% -6.25%
Aug-23-23 01:04PM	Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance (GuruFocus.com) +17.19%
08:00AM	Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023 (PR Newswire)
Aug-08-23 04:43PM	Regulus: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates (PR Newswire)
Aug-02-23 08:00AM	Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (PR Newswire)
Jul-18-23 08:00AM	Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference (PR Newswire)
Jun-27-23 08:00AM	Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +6.72%
Jun-23-23 08:00AM	Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors (PR Newswire)
Jun-20-23 08:00AM	Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital (PR Newswire) -8.67%
Jun-12-23 08:00AM	Regulus Therapeutics Strengthens Research & Development Leadership (PR Newswire) +8.15%
May-16-23 08:00AM	Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -6.45%
May-11-23 04:18PM	Regulus: Q1 Earnings Snapshot (AP Finance) +15.33%
04:05PM	Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates (PR Newswire)
Apr-13-23 08:00AM	Regulus Therapeutics Announces $15 Million Private Placement of Equity (PR Newswire) +35.54%
Apr-12-23 04:05PM	Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -6.24%
Mar-23-23 04:52PM	Regulus: Q4 Earnings Snapshot (AP Finance) -8.49%
04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates (PR Newswire)
Feb-09-23 08:00AM	Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference (PR Newswire)
Jan-13-23 04:05PM	Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.70%
Jan-09-23 06:01AM	Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics (Benzinga)
Dec-12-22 08:00AM	Regulus Therapeutics Announces Resignation of Board Member (PR Newswire) +8.70%
Nov-29-22 05:43PM	13 Best Biotech Penny Stocks To Buy Now (Insider Monkey)
08:00AM	Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations (PR Newswire)
Nov-10-22 04:05PM	Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates (PR Newswire)
Nov-03-22 08:00AM	Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call (PR Newswire) -5.52%
Nov-02-22 08:00AM	Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -8.07%
Sep-13-22 11:58AM	Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study (Zacks) +10.31%
Sep-12-22 11:14AM	Regulus Shares Surge After Early-Stage RGLS8429 Data In Rare Kidney Disease (Benzinga) +15.48%
08:00AM	Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Sep-02-22 04:05PM	Regulus Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire) +5.19% +14.08%
Aug-11-22 04:10PM	Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates (PR Newswire)
Aug-04-22 08:00AM	Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call (PR Newswire) +14.09%
Jun-21-22 08:00AM	Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Jun-13-22 08:00AM	Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Jun-02-22 08:00AM	Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK (PR Newswire)
May-17-22 04:30PM	Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference (PR Newswire) +6.56%
07:00AM	7 Penny Stocks With 10x Potential This Year (InvestorPlace)

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Collier Kathryn J	Director	Jun 17 '25	Option Exercise	9.38	4,929	46,240	65,240	Jun 18 05:00 PM
Collier Kathryn J	Director	Jun 16 '25	Option Exercise	9.90	1,396	13,820	67,844	Jun 18 05:00 PM
Klassen Preston	President & Head of R & D	Jun 03 '25	Buy	7.99	12,000	95,852	48,055	Jun 04 05:00 PM
Hagan Joseph P	Chief Executive Officer	Jan 30 '25	Buy	1.09	50,000	54,260	260,808	Jan 31 05:00 PM
BALTIMORE DAVID	Director	Jan 30 '25	Buy	1.06	19,610	20,787	22,169	Jan 31 05:00 PM
Aker Christopher Ray	Sr. VP & General Counsel	Jan 13 '25	Sale	1.26	38,547	48,693	54,634	Jan 15 05:00 PM
Aker Christopher Ray	Sr. VP & General Counsel	Jan 14 '25	Sale	1.26	5,088	6,427	49,546	Jan 15 05:00 PM
Hagan Joseph P	Chief Executive Officer	Jan 13 '25	Sale	1.26	115,290	145,634	222,572	Jan 15 05:00 PM
Hagan Joseph P	Chief Executive Officer	Jan 14 '25	Sale	1.26	11,764	14,860	210,808	Jan 15 05:00 PM
CALSADA CRISPINA	Chief Financial Officer	Jan 13 '25	Sale	1.26	38,716	48,906	50,566	Jan 15 05:00 PM
CALSADA CRISPINA	Chief Financial Officer	Jan 14 '25	Sale	1.26	5,088	6,427	45,478	Jan 15 05:00 PM
Klassen Preston	President & Head of R & D	Jan 13 '25	Sale	1.26	31,445	39,721	36,055	Jan 15 05:00 PM
Collier Kathryn J	Director	Jul 25 '24	Buy	1.82	4,000	7,280	6,740	Jul 29 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGLS

Regulus Therapeutics Inc

Upgrade your FINVIZ experience